McColl S R, Paquin R, Ménard C, Beaulieu A D
Centre de Recherche en Inflammation, Université Laval, Québec, Canada.
J Exp Med. 1992 Aug 1;176(2):593-8. doi: 10.1084/jem.176.2.593.
Neutrophils, an abundant cell type at sites of inflammation, have the ability to produce a number of cytokines, including interleukin 1 (IL-1), IL-8, granulocyte-macrophage colony-stimulating factor (GM-CSF), and tumor necrosis factor alpha (TNF-alpha). In this study, we have examined the ability of human neutrophils to produce the IL-1 receptor antagonist (IL-1Ra), a 17-23-kD protein recently isolated and cloned from macrophages. Since IL-1Ra has been shown to inhibit both the in vitro and in vivo effects of IL-1, its production by large numbers of tissue-invading neutrophils might provide a mechanism by which the effects of IL-1 are regulated in inflammation. Using antibodies that are specific for IL-1Ra and a cDNA probe encoding for this protein, we were able to show that neutrophils constitutively produce IL-1Ra. However, after activation by GM-CSF and TNF-alpha, IL-1Ra was secreted into the extracellular milieu where it constituted the major de novo synthesized product of activated neutrophils. None of a large array of other potent neutrophil agonists were found to affect the production of IL-1Ra by neutrophils. Quantitative measurements by enzyme-linked immunosorbent assay revealed that intracellular IL-1Ra is in eightfold excess of the amount secreted in supernatants when studying nonactivated neutrophils. However, in GM-CSF- and TNF-alpha-activated cells, this difference was reduced to values between four- and fivefold, as virtually all of the de novo synthesized IL-1Ra was secreted. In activated cells, the intracellular content of IL-1Ra was found to be in the 2-2.5-ng/ml range per 10(6) neutrophils, whereas levels reached the 0.5-ng/ml range in supernatants. This would imply that IL-1Ra is produced in excess of IL-1 by a factor of at least 100, an observation that is in agreement with the reported amounts of IL-1Ra needed to inhibit the proinflammatory effects of IL-1. Neutrophils isolated from an inflammatory milieu, the synovial fluid of patients with rheumatoid arthritis, were found to respond to GM-CSF and TNF-alpha in terms of IL-1Ra synthesis, indicating that the in vitro observations made in this study are likely to occur in an inflammatory setting in vivo.
中性粒细胞是炎症部位数量丰富的细胞类型,能够产生多种细胞因子,包括白细胞介素1(IL-1)、IL-8、粒细胞-巨噬细胞集落刺激因子(GM-CSF)和肿瘤坏死因子α(TNF-α)。在本研究中,我们检测了人中性粒细胞产生IL-1受体拮抗剂(IL-1Ra)的能力,IL-1Ra是一种最近从巨噬细胞中分离和克隆的17 - 23kD蛋白。由于IL-1Ra已被证明能抑制IL-1的体外和体内效应,大量侵入组织的中性粒细胞产生IL-1Ra可能提供了一种在炎症中调节IL-1效应的机制。使用针对IL-1Ra的特异性抗体和编码该蛋白的cDNA探针,我们能够证明中性粒细胞组成性地产生IL-1Ra。然而,在被GM-CSF和TNF-α激活后,IL-1Ra分泌到细胞外环境中,它构成了激活的中性粒细胞主要的从头合成产物。未发现大量其他有效的中性粒细胞激动剂会影响中性粒细胞产生IL-1Ra。通过酶联免疫吸附测定进行的定量测量显示,在研究未激活的中性粒细胞时,细胞内IL-1Ra的量比上清液中分泌的量高出八倍。然而,在GM-CSF和TNF-α激活的细胞中,这种差异降至四到五倍,因为几乎所有从头合成的IL-1Ra都被分泌了。在激活的细胞中,每10^6个中性粒细胞中IL-1Ra的细胞内含量在2 - 2.5 ng/ml范围内,而上清液中的水平达到0.5 ng/ml范围。这意味着IL-1Ra的产生量比IL-1至少高出100倍,这一观察结果与报道的抑制IL-1促炎作用所需的IL-1Ra量一致。从炎症环境(类风湿性关节炎患者的滑液)中分离出的中性粒细胞在IL-1Ra合成方面对GM-CSF和TNF-α有反应,表明本研究中的体外观察结果可能在体内炎症环境中发生。